Novartis Suffers Second Major Trial Defeat, Intensifying Pressure on Pipeline and CEO
Novartis reported that del-desiran, acquired via its $12 billion purchase of Avidity, failed to meet the primary endpoint in a Phase III trial for myotonic dystrophy type 1, marking the company's second major trial disappointment in days. The announcement pushed shares sharply lower, erased roughly 24 billion Swiss francs of market value, and compo…